6.2.1.2. active surveillance. active surveillance aims delay completely avoid unnecessary treatment, consequently unnecessary side effects, men clinically localised pca, life expectancy ten years more, require immediate treatment, time achieve correct timing curative treatment eventually . patients remain close surveillance structured surveillance programmes regular follow-up consisting psa testing, clinical examination, mri imaging repeat prostate biopsies, curative treatment prompted pre-defined thresholds indicative development potentially significant disease, still curable, considering individual life expectancy. formal rct available comparing curative treatment. several cohorts investigated organ-confined disease, findings summarised sr . largest prospective series men low-risk pca managed published . table 6.1.2 summarises results selective cohorts. clear long-term os css patients extremely good. however, one-third patients ‘reclassified’ follow-up, undergo curative treatment due disease upgrading, increase disease extent, disease stage, progression, patient preference. considerable variation heterogeneity studies regarding patient selection eligibility, follow-up policies (including frequency type imaging mri imaging, type frequency repeat prostate biopsies, mri-targeted biopsies transperineal template biopsies, use psa kinetics density, frequency clinical follow-up), active treatment instigated (i.e., reclassification criteria) outcome measures prioritised . specific guidelines inclusion criteria follow-up strategies as, see sections 6.2.1.2. protect rct, 1,643 patients randomised one three arms: active treatment either rp ebrt outcomes reported ten years 15 years . even though protect trial rct not, strictly speaking, study comparing active treatment include formal strategy described sections 6.2.1.2. active monitoring (am), used study, significantly less stringent surveillance strategy terms clinical follow-up, using psa only, relaxed criteria define progression. imaging repeat biopsies performed as. enrolment fifty-six percent patients low-risk disease, 90% psa < 10 ng/ml, 77% isup grade group 1 (20% isup grade group 2–3), 76% t1c disease. remaining patients mainly intermediate-risk disease. key finding effective active treatment 15 years (css = 96.9% am-group vs. 97.8% rp-group 97.1% ebrt-group, p=0.53), cost increased metastatic progression risk (9.4% vs. 4.7% 5.0% respectively), well clinical progression 15 years (25.9% vs. 10.7% rp/rt). death cause occurred 21.7% cohort, similar numbers across treatment groups. metastases, although rare, frequent seen comparable protocols . comprehensive characterisation protect study cohort performed ten years, stratifying patients baseline according risk progression using clinical stage, grade diagnosis psa level . additionally, detailed clinico-pathological information participants received rp analysed. 15-year paper reported updated contemporary risk-stratification according d’amico (24.1% intermediate risk, 9.6% high risk), capra (26.4% score 3-5, 2.5% score 6-10) cambridge prognostic group (20.5% group 2, 8.8% groups 3-5). among patients underwent prostatectomy, 50.5% isup grade group ≥2, 28.5% increase pathological stage 32% increase tumour grade. additionally, 51% patients developed metastases displayed isup grade group 1 47.6% low capra risk. time, 61.1% patients group received radical treatment (from 54.8% ten years). ten year report authors aimed identify prognostic markers. results showed treatment received, age (65–69 vs. 50–64 years), psa, isup grade group diagnosis, ct stage, risk group, number pca-involved biopsy cores, maximum length tumour (median 5.0 vs. 3.0 mm), aggregate length tumour (median 8.0 vs. 4.0 mm), presence perineural invasion associated increased risk disease progression (p < 0.001 each). however, factors could reliably predict progression individuals. notably, 53% (n = 105) patients progressed biopsy isup grade group 1 disease, although, conversely, none participants received rp subsequently progressed pathological isup grade group 1 tumours. discrepancy progression metastases rate arm protect study comparable protocols can, likely, explained inadequate sampling psa testing 10-core trus-guided biopsies differences intensity surveillance. important note arm protect represented intermediate approach contemporary protocols ww terms monitoring strategy based almost entirely psa measurements alone; use mri scan, either recruitment monitoring period, protocol-mandated repeat prostate biopsies regular intervals. addition, approximately 40% randomised patients intermediate-risk disease (both isup grade group 2 3). nevertheless, protect study reinforced role deferred active treatment (i.e., either form initial am) feasible alternative active curative interventions patients low-grade low-stage disease, well many patients favourable intermediate risk disease. beyond 15 years, rct-data available, yet, although likely give reassurance especially younger men, based accurate risk stratification recruitment stringent criteria regarding follow-up, imaging, repeat biopsy reclassification. individual life expectancy must continuously evaluated considering active treatment low-risk patients ten 15 years’ individual life expectancy .